# Research Progress of ALK Activation Pattern Changes and Targeted Therapy in Advanced Lung Cancer

## TL;DR

This paper reviews how changes in the ALK gene affect lung cancer treatment and discusses progress in targeted therapies for patients with ALK mutations.

## Contribution

The paper provides an updated overview of ALK gene variations and their impact on targeted therapy outcomes in advanced lung cancer.

## Key findings

- ALK fusion is the most common type of ALK gene alteration in lung cancer.
- Different ALK mutations affect treatment response and drug resistance differently.
- ALK-TKIs have significantly improved survival for patients with ALK-positive lung cancer.

## Abstract

肺癌是我国乃至全球发病率最高的癌种，也是导致癌症死亡的主要原因。存在间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）基因改变的患者有机会接受分子靶向治疗，以ALK为靶点的药物，即ALK-酪氨酸激酶抑制剂（ALK-tyrosine kinase inhibitors, ALK-TKIs），很大程度上延长了患者的生存期。ALK基因变异类型包括点突变、扩增、融合/重排，ALK融合较其他类型更为常见。但是，各类型的基因改变在分子靶向治疗时效果有所不同，据此，本文分别介绍了ALK基因不同变异形式的相关内容，重点介绍靶向治疗的研究进展，对未来的发展方向提出探讨。

Differences in ALK fusion partners and sensitivity to targeted therapy

Mutation sites of drug resistance in ALK kinase domain